Literature DB >> 2596372

The inhibition of 5-lipoxygenase by RG 6866.

G W Carnathan1, D M Sweeney, J J Travis, R J Gordon, C A Sutherland, N Jariwala, M Clearfield, S O'Rourke, F C Huang, R G Van Inwegen.   

Abstract

The generation of leukotrienes C4, D4 and E4 from arachidonic acid is dependent upon the activity of 5-lipoxygenase (5-LOX). The effects of RG 6866 (N-methyl-4-benzyloxyphenylacetohydroxamic acid) on the activity of guinea pig 5-LOX in vitro and in vivo were determined in the present study. The generation of 5-hydroxy-6,8,11,14-eicosatetraenoic acid (5-HETE) from arachidonic acid by isolated guinea pig peritoneal polymorphonuclear (PMN) cells was inhibited by incubation with RG 6866 (IC50 = 0.20 microM). A similar effect (IC50 = 0.23 microM) was observed when 5-HETE production was measured in a supernatant fraction from PMNs. Additionally, the compound did not inhibit 3H-LTD4 binding to guinea pig membranes. In actively sensitized guinea pigs pretreated with indomethacin, propranolol and pyrilamine, RG 6866 inhibited antigen-induced systemic anaphylaxis and LTD4-dependent bronchoconstriction in a dose-dependent manner following oral administration. In the pulmonary anaphylaxis model, significant (p less than 0.05) inhibition of the mortality was observed within 30 min and maintained through four hours after treatment with RG 6866 (50 mg/kg i.g.). Finally, orally administered RG 6866 inhibited the formation of LTC4 in these animals with an ED50 = 24.0 mg/kg. These findings indicate that RG 6866 is an inhibitor of 5-LOX both in vitro and in vivo.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2596372     DOI: 10.1007/bf01967402

Source DB:  PubMed          Journal:  Agents Actions        ISSN: 0065-4299


  18 in total

1.  In vitro pharmacology of ICI 198,615: a novel, potent and selective peptide leukotriene antagonist.

Authors:  D W Snyder; R E Giles; R A Keith; Y K Yee; R D Krell
Journal:  J Pharmacol Exp Ther       Date:  1987-11       Impact factor: 4.030

2.  Antagonism of antigen-induced contraction of isolated guinea-pig trachea by 5-lipoxygenase inhibitors.

Authors:  J M Hand; S F Schwalm; A J Lewis
Journal:  Int Arch Allergy Appl Immunol       Date:  1986

3.  In vitro and in vivo mechanisms of leukotriene-mediated bronchoconstriction in the guinea pig.

Authors:  B M Weichman; R M Muccitelli; R R Osborn; D A Holden; J G Gleason; M A Wasserman
Journal:  J Pharmacol Exp Ther       Date:  1982-07       Impact factor: 4.030

4.  Actions of bronchodilator drugs, glucocorticoid, and their combinations on airways in rats and guinea pigs.

Authors:  R O Salonen
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1985

5.  Slow-reacting substances (leukotrienes) contract human airway and pulmonary vascular smooth muscle in vitro.

Authors:  C J Hanna; M K Bach; P D Pare; R R Schellenberg
Journal:  Nature       Date:  1981-03-26       Impact factor: 49.962

6.  Effects of a 5-lipoxygenase inhibitor (L-651,392) on primary and late pulmonary responses to ascaris antigen in the squirrel monkey.

Authors:  C S McFarlane; R Hamel; A W Ford-Hutchinson
Journal:  Agents Actions       Date:  1987-10

7.  Antigen-induced bronchial anaphylaxis in actively sensitized guinea-pigs: effect of long-term treatment with sodium cromoglycate and aminophylline.

Authors:  P Andersson; H Bergstrand
Journal:  Br J Pharmacol       Date:  1981-11       Impact factor: 8.739

8.  The release of leukotriene B4 during experimental inflammation.

Authors:  P M Simmons; J A Salmon; S Moncada
Journal:  Biochem Pharmacol       Date:  1983-04-15       Impact factor: 5.858

9.  Antagonism of the in vivo and in vitro effects of leukotriene D4 by SC-39070 in guinea pigs.

Authors:  G W Carnathan; J H Sanner; J M Thompson; C M Prusa; M Miyano
Journal:  Agents Actions       Date:  1987-02

10.  REV 5901: an orally effective peptidoleukotriene antagonist, detailed biochemical/pharmacological profile.

Authors:  R G Van Inwegen; A Khandwala; R Gordon; P Sonnino; S Coutts; S Jolly
Journal:  J Pharmacol Exp Ther       Date:  1987-04       Impact factor: 4.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.